Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer

HER2 is an important predictive marker for response to trastuzumab and lapatinib in breast cancer. It is also a powerful prognostic marker in node-positive patients. Although standardized assays are used to help select patients for anti-HER2 therapy, there are no standardized criteria for assessing...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gilcrease, Michael Z., Woodward, Wendy A., Nicolas, Marlo M., Corley, Lynda J., Fuller, Gregory N., Esteva, Francisco J., Tucker, Susan L., Buchholz, Thomas A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3063383/
https://ncbi.nlm.nih.gov/pubmed/19252432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PAS.0b013e31819437f9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados